ReviewFuture oncology (London, England)2024
Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy.
John Nemunaitis et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papertrialcites it
ReviewFuture oncology (London, England)2024
John Nemunaitis et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.